Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis
James May, … , Jane A. Mitchell, R. Gisli Jenkins
James May, … , Jane A. Mitchell, R. Gisli Jenkins
Published September 15, 2023
Citation Information: J Clin Invest. 2023;133(18):e172058. https://doi.org/10.1172/JCI172058.
View: Text | PDF
Review Article has an altmetric score of 14

Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease of the lung with poor survival. The incidence and mortality of IPF are rising, but treatment remains limited. Currently, two drugs can slow the scarring process but often at the expense of intolerable side effects, and without substantially changing overall survival. A better understanding of mechanisms underlying IPF is likely to lead to improved therapies. The current paradigm proposes that repetitive alveolar epithelial injury from noxious stimuli in a genetically primed individual is followed by abnormal wound healing, including aberrant activity of extracellular matrix–secreting cells, with resultant tissue fibrosis and parenchymal damage. However, this may underplay the importance of the vascular contribution to fibrogenesis. The lungs receive 100% of the cardiac output, and vascular abnormalities in IPF include (a) heterogeneous vessel formation throughout fibrotic lung, including the development of abnormal dilated vessels and anastomoses; (b) abnormal spatially distributed populations of endothelial cells (ECs); (c) dysregulation of endothelial protective pathways such as prostacyclin signaling; and (d) an increased frequency of common vascular and metabolic comorbidities. Here, we propose that vascular and EC abnormalities are both causal and consequential in the pathobiology of IPF and that fuller evaluation of dysregulated pathways may lead to effective therapies and a cure for this devastating disease.

Authors

James May, Jane A. Mitchell, R. Gisli Jenkins

×

Figure 3

Vascular signaling pathways regulate fibrosis via GPCR, NO, intracellular (PPAR) receptors, and surface integrins in IPF.

Options: View larger image (or click on image) Download as PowerPoint
Vascular signaling pathways regulate fibrosis via GPCR, NO, intracellula...
(A) Drugs that may counter fibrosis can act through signaling pathways in a range of vascular cell types, including ECs, VSMCs, and fibroblasts. Fibrogenesis-promoting pathways involve GPCRs or NO and signal through cAMP or cGMP to induce fibrosis-related transcriptional events. Treprostinil (TP) acts on cell surface GPCRs to increase intracellular cAMP, which can affect transcription of actin-encoding genes that affect the cytoskeleton, cell motility, and adhesion. TP can also directly activate intracellular PPAR receptors to modulate gene expression. PDE inhibitors (BI-1015550 and sildenafil) prevent cAMP and cGMP breakdown. cGMP, generated following exposure to endogenous NO, activates PKG, which affects gene transcription, the cytoskeleton, and cell contraction. Stimulators, including riociguat, can also generate cGMP. The ET antagonists bosentan and ambrisentan block GPCRs to reduce intracellular Ca2+ concentrations and PKC activity, again modulating gene expression. (B) Therapeutics in IPF can signal through pathways affecting TGF-β signaling or other mechanisms promoting profibrotic gene expression. Ziritaxestat blocks autotaxin, from which LPA is generated. LPA induces various profibrotic effects via GPCRs, including increased RhoA activity and actin cytoskeleton rearrangements that promote altered cell motility in a range of cells relevant to fibrosis. Belumosudil preferentially blocks the ROCK2 isoform. The cytoskeleton can activate cell surface integrins, which are implicated in TGF-β activation. Integrins can be directly blocked by bexotegrast. CTGF, which has numerous profibrotic signaling effects, can be neutralized by the monoclonal antibody pamrevlumab. ATR2 agonists affect numerous intracellular phosphatases, which affect downstream profibrotic gene expression.